img

Endogenous Peptide Substances - Global Market insights and Sales Trends 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Endogenous Peptide Substances - Global Market insights and Sales Trends 2024

Global Endogenous Peptide Substances market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Research and Medicine are the major drivers for the industry.
The driving force of endogenous peptides mainly comes from the following aspects
Biological functions of bioactive peptidesBioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.
Demand for drug research and developmentWith the development of medical technology, people's demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.
Progress in production technologySince the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.
Expansion of indicationsAs the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in anti-aging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Endogenous Peptide Substances market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


Assertio Therapeutics Inc.
Cipher Pharmaceuticals Inc.
Endo International Plc
Biosynth Carbosynth
Lannett Co. Inc.
Pfizer
Johnson & Johnson
Peptide Institute
Abbexa
Phoenix Pharmaceuticals
Creative Peptides
Segment by Type
Neuropeptides
Hormones
Cytokines
Peptide Hormones
Bioactive Peptides

Segment by Application


Research
Medicine
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Endogenous Peptide Substances market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Endogenous Peptide Substances introduction, etc. Endogenous Peptide Substances Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Endogenous Peptide Substances market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.

Table of Content

1 Market Overview of Endogenous Peptide Substances
1.1 Endogenous Peptide Substances Market Overview
1.1.1 Endogenous Peptide Substances Product Scope
1.1.2 Endogenous Peptide Substances Market Status and Outlook
1.2 Global Endogenous Peptide Substances Market Size Overview by Region 2018 VS 2022 VS 2033
1.3 Global Endogenous Peptide Substances Market Size by Region (2018-2033)
1.4 Global Endogenous Peptide Substances Historic Market Size by Region (2018-2023)
1.5 Global Endogenous Peptide Substances Market Size Forecast by Region (2024-2033)
1.6 Key Regions, Endogenous Peptide Substances Market Size (2018-2033)
1.6.1 North America Endogenous Peptide Substances Market Size (2018-2033)
1.6.2 Europe Endogenous Peptide Substances Market Size (2018-2033)
1.6.3 Asia-Pacific Endogenous Peptide Substances Market Size (2018-2033)
1.6.4 Latin America Endogenous Peptide Substances Market Size (2018-2033)
1.6.5 Middle East & Africa Endogenous Peptide Substances Market Size (2018-2033)
2 Endogenous Peptide Substances Market by Type
2.1 Introduction
2.1.1 Neuropeptides
2.1.2 Hormones
2.1.3 Cytokines
2.1.4 Peptide Hormones
2.1.5 Bioactive Peptides
2.2 Global Endogenous Peptide Substances Market Size by Type: 2018 VS 2022 VS 2033
2.2.1 Global Endogenous Peptide Substances Historic Market Size by Type (2018-2023)
2.2.2 Global Endogenous Peptide Substances Forecasted Market Size by Type (2024-2033)
2.3 Key Regions Market Size by Type
2.3.1 North America Endogenous Peptide Substances Revenue Breakdown by Type (2018-2033)
2.3.2 Europe Endogenous Peptide Substances Revenue Breakdown by Type (2018-2033)
2.3.3 Asia-Pacific Endogenous Peptide Substances Revenue Breakdown by Type (2018-2033)
2.3.4 Latin America Endogenous Peptide Substances Revenue Breakdown by Type (2018-2033)
2.3.5 Middle East and Africa Endogenous Peptide Substances Revenue Breakdown by Type (2018-2033)
3 Endogenous Peptide Substances Market Overview by Application
3.1 Introduction
3.1.1 Research
3.1.2 Medicine
3.1.3 Others
3.2 Global Endogenous Peptide Substances Market Size by Application: 2018 VS 2022 VS 2033
3.2.1 Global Endogenous Peptide Substances Historic Market Size by Application (2018-2023)
3.2.2 Global Endogenous Peptide Substances Forecasted Market Size by Application (2024-2033)
3.3 Key Regions Market Size by Application
3.3.1 North America Endogenous Peptide Substances Revenue Breakdown by Application (2018-2033)
3.3.2 Europe Endogenous Peptide Substances Revenue Breakdown by Application (2018-2033)
3.3.3 Asia-Pacific Endogenous Peptide Substances Revenue Breakdown by Application (2018-2033)
3.3.4 Latin America Endogenous Peptide Substances Revenue Breakdown by Application (2018-2033)
3.3.5 Middle East and Africa Endogenous Peptide Substances Revenue Breakdown by Application (2018-2033)
4 Endogenous Peptide Substances Competition Analysis by Players
4.1 Global Endogenous Peptide Substances Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Endogenous Peptide Substances as of 2022)
4.3 Date of Key Players Enter into Endogenous Peptide Substances Market
4.4 Global Top Players Endogenous Peptide Substances Headquarters and Area Served
4.5 Key Players Endogenous Peptide Substances Product Solution and Service
4.6 Competitive Status
4.6.1 Endogenous Peptide Substances Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Assertio Therapeutics Inc.
5.1.1 Assertio Therapeutics Inc. Profile
5.1.2 Assertio Therapeutics Inc. Main Business
5.1.3 Assertio Therapeutics Inc. Endogenous Peptide Substances Products, Services and Solutions
5.1.4 Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue (US$ Million) & (2018-2023)
5.1.5 Assertio Therapeutics Inc. Recent Developments
5.2 Cipher Pharmaceuticals Inc.
5.2.1 Cipher Pharmaceuticals Inc. Profile
5.2.2 Cipher Pharmaceuticals Inc. Main Business
5.2.3 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Products, Services and Solutions
5.2.4 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue (US$ Million) & (2018-2023)
5.2.5 Cipher Pharmaceuticals Inc. Recent Developments
5.3 Endo International Plc
5.3.1 Endo International Plc Profile
5.3.2 Endo International Plc Main Business
5.3.3 Endo International Plc Endogenous Peptide Substances Products, Services and Solutions
5.3.4 Endo International Plc Endogenous Peptide Substances Revenue (US$ Million) & (2018-2023)
5.3.5 Biosynth Carbosynth Recent Developments
5.4 Biosynth Carbosynth
5.4.1 Biosynth Carbosynth Profile
5.4.2 Biosynth Carbosynth Main Business
5.4.3 Biosynth Carbosynth Endogenous Peptide Substances Products, Services and Solutions
5.4.4 Biosynth Carbosynth Endogenous Peptide Substances Revenue (US$ Million) & (2018-2023)
5.4.5 Biosynth Carbosynth Recent Developments
5.5 Lannett Co. Inc.
5.5.1 Lannett Co. Inc. Profile
5.5.2 Lannett Co. Inc. Main Business
5.5.3 Lannett Co. Inc. Endogenous Peptide Substances Products, Services and Solutions
5.5.4 Lannett Co. Inc. Endogenous Peptide Substances Revenue (US$ Million) & (2018-2023)
5.5.5 Lannett Co. Inc. Recent Developments
5.6 Pfizer
5.6.1 Pfizer Profile
5.6.2 Pfizer Main Business
5.6.3 Pfizer Endogenous Peptide Substances Products, Services and Solutions
5.6.4 Pfizer Endogenous Peptide Substances Revenue (US$ Million) & (2018-2023)
5.6.5 Pfizer Recent Developments
5.7 Johnson & Johnson
5.7.1 Johnson & Johnson Profile
5.7.2 Johnson & Johnson Main Business
5.7.3 Johnson & Johnson Endogenous Peptide Substances Products, Services and Solutions
5.7.4 Johnson & Johnson Endogenous Peptide Substances Revenue (US$ Million) & (2018-2023)
5.7.5 Johnson & Johnson Recent Developments
5.8 Peptide Institute
5.8.1 Peptide Institute Profile
5.8.2 Peptide Institute Main Business
5.8.3 Peptide Institute Endogenous Peptide Substances Products, Services and Solutions
5.8.4 Peptide Institute Endogenous Peptide Substances Revenue (US$ Million) & (2018-2023)
5.8.5 Peptide Institute Recent Developments
5.9 Abbexa
5.9.1 Abbexa Profile
5.9.2 Abbexa Main Business
5.9.3 Abbexa Endogenous Peptide Substances Products, Services and Solutions
5.9.4 Abbexa Endogenous Peptide Substances Revenue (US$ Million) & (2018-2023)
5.9.5 Abbexa Recent Developments
5.10 Phoenix Pharmaceuticals
5.10.1 Phoenix Pharmaceuticals Profile
5.10.2 Phoenix Pharmaceuticals Main Business
5.10.3 Phoenix Pharmaceuticals Endogenous Peptide Substances Products, Services and Solutions
5.10.4 Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue (US$ Million) & (2018-2023)
5.10.5 Phoenix Pharmaceuticals Recent Developments
5.11 Creative Peptides
5.11.1 Creative Peptides Profile
5.11.2 Creative Peptides Main Business
5.11.3 Creative Peptides Endogenous Peptide Substances Products, Services and Solutions
5.11.4 Creative Peptides Endogenous Peptide Substances Revenue (US$ Million) & (2018-2023)
5.11.5 Creative Peptides Recent Developments
6 North America
6.1 North America Endogenous Peptide Substances Market Size by Country (2018-2033)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Endogenous Peptide Substances Market Size by Country (2018-2033)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Endogenous Peptide Substances Market Size by Region (2018-2033)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Endogenous Peptide Substances Market Size by Country (2018-2033)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Endogenous Peptide Substances Market Size by Country (2018-2033)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Endogenous Peptide Substances Market Dynamics
11.1 Endogenous Peptide Substances Industry Trends
11.2 Endogenous Peptide Substances Market Drivers
11.3 Endogenous Peptide Substances Market Challenges
11.4 Endogenous Peptide Substances Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Endogenous Peptide Substances Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2033
Table 2. Global Endogenous Peptide Substances Market Size by Region (2018-2023) & (US$ Million)
Table 3. Global Endogenous Peptide Substances Market Size Share by Region (2018-2023)
Table 4. Global Endogenous Peptide Substances Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 5. Global Endogenous Peptide Substances Forecasted Market Size Share by Region (2024-2033)
Table 6. Global Endogenous Peptide Substances Market Size (US$ Million) by Type: 2018 VS 2022 VS 2033
Table 7. Global Endogenous Peptide Substances Market Size by Type (2018-2023) & (US$ Million)
Table 8. Global Endogenous Peptide Substances Revenue Market Share by Type (2018-2023)
Table 9. Global Endogenous Peptide Substances Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 10. Global Endogenous Peptide Substances Revenue Market Share by Type (2024-2033)
Table 11. North America Endogenous Peptide Substances Revenue by Type (2018-2023) & (US$ Million)
Table 12. North America Endogenous Peptide Substances Revenue by Type (2024-2033) & (US$ Million)
Table 13. Europe Endogenous Peptide Substances Revenue by Type (2018-2023) & (US$ Million)
Table 14. Europe Endogenous Peptide Substances Revenue by Type (2024-2033) & (US$ Million)
Table 15. Asia-Pacific Endogenous Peptide Substances Revenue by Type (2018-2023) & (US$ Million)
Table 16. Asia-Pacific Endogenous Peptide Substances Revenue by Type (2024-2033) & (US$ Million)
Table 17. Latin America Endogenous Peptide Substances Revenue by Type (2018-2023) & (US$ Million)
Table 18. Latin America Endogenous Peptide Substances Revenue by Type (2024-2033) & (US$ Million)
Table 19. Middle East and Africa Endogenous Peptide Substances Revenue by Type (2018-2023) & (US$ Million)
Table 20. Middle East and Africa Endogenous Peptide Substances Revenue by Type (2024-2033) & (US$ Million)
Table 21. Global Endogenous Peptide Substances Market Size (US$ Million) by Application: 2018 VS 2022 VS 2033
Table 22. Global Endogenous Peptide Substances Market Size by Application (2018-2023) & (US$ Million)
Table 23. Global Endogenous Peptide Substances Revenue Market Share by Application (2018-2023)
Table 24. Global Endogenous Peptide Substances Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 25. Global Endogenous Peptide Substances Revenue Market Share by Application (2024-2033)
Table 26. North America Endogenous Peptide Substances Revenue by Application (2018-2023) & (US$ Million)
Table 27. North America Endogenous Peptide Substances Revenue by Application (2024-2033) & (US$ Million)
Table 28. Europe Endogenous Peptide Substances Revenue by Application (2018-2023) & (US$ Million)
Table 29. Europe Endogenous Peptide Substances Revenue by Application (2024-2033) & (US$ Million)
Table 30. Asia-Pacific Endogenous Peptide Substances Revenue by Application (2018-2023) & (US$ Million)
Table 31. Asia-Pacific Endogenous Peptide Substances Revenue by Application (2024-2033) & (US$ Million)
Table 32. Latin America Endogenous Peptide Substances Revenue by Application (2018-2023) & (US$ Million)
Table 33. Latin America Endogenous Peptide Substances Revenue by Application (2024-2033) & (US$ Million)
Table 34. Middle East and Africa Endogenous Peptide Substances Revenue by Application (2018-2023) & (US$ Million)
Table 35. Middle East and Africa Endogenous Peptide Substances Revenue by Application (2024-2033) & (US$ Million)
Table 36. Global Endogenous Peptide Substances Revenue (US$ Million) by Players (2018-2023)
Table 37. Global Endogenous Peptide Substances Revenue Market Share by Players (2018-2023)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Endogenous Peptide Substances as of 2022)
Table 39. Date of Key Players Enter into Endogenous Peptide Substances Market
Table 40. Global Endogenous Peptide Substances Key Players Headquarters and Area Served
Table 41. Endogenous Peptide Substances Product Solution and Service
Table 42. Global Endogenous Peptide Substances Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Assertio Therapeutics Inc. Basic Information List
Table 45. Assertio Therapeutics Inc. Description and Business Overview
Table 46. Assertio Therapeutics Inc. Endogenous Peptide Substances Products, Services and Solutions
Table 47. Revenue (US$ Million) in Endogenous Peptide Substances Business of Assertio Therapeutics Inc. (2018-2023)
Table 48. Assertio Therapeutics Inc. Recent Developments
Table 49. Cipher Pharmaceuticals Inc. Basic Information List
Table 50. Cipher Pharmaceuticals Inc. Description and Business Overview
Table 51. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Products, Services and Solutions
Table 52. Revenue (US$ Million) in Endogenous Peptide Substances Business of Cipher Pharmaceuticals Inc. (2018-2023)
Table 53. Cipher Pharmaceuticals Inc. Recent Developments
Table 54. Endo International Plc Basic Information List
Table 55. Endo International Plc Description and Business Overview
Table 56. Endo International Plc Endogenous Peptide Substances Products, Services and Solutions
Table 57. Revenue (US$ Million) in Endogenous Peptide Substances Business of Endo International Plc (2018-2023)
Table 58. Endo International Plc Recent Developments
Table 59. Biosynth Carbosynth Basic Information List
Table 60. Biosynth Carbosynth Description and Business Overview
Table 61. Biosynth Carbosynth Endogenous Peptide Substances Products, Services and Solutions
Table 62. Revenue (US$ Million) in Endogenous Peptide Substances Business of Biosynth Carbosynth (2018-2023)
Table 63. Biosynth Carbosynth Recent Developments
Table 64. Lannett Co. Inc. Basic Information List
Table 65. Lannett Co. Inc. Description and Business Overview
Table 66. Lannett Co. Inc. Endogenous Peptide Substances Products, Services and Solutions
Table 67. Revenue (US$ Million) in Endogenous Peptide Substances Business of Lannett Co. Inc. (2018-2023)
Table 68. Lannett Co. Inc. Recent Developments
Table 69. Pfizer Basic Information List
Table 70. Pfizer Description and Business Overview
Table 71. Pfizer Endogenous Peptide Substances Products, Services and Solutions
Table 72. Revenue (US$ Million) in Endogenous Peptide Substances Business of Pfizer (2018-2023)
Table 73. Pfizer Recent Developments
Table 74. Johnson & Johnson Basic Information List
Table 75. Johnson & Johnson Description and Business Overview
Table 76. Johnson & Johnson Endogenous Peptide Substances Products, Services and Solutions
Table 77. Revenue (US$ Million) in Endogenous Peptide Substances Business of Johnson & Johnson (2018-2023)
Table 78. Johnson & Johnson Recent Developments
Table 79. Peptide Institute Basic Information List
Table 80. Peptide Institute Description and Business Overview
Table 81. Peptide Institute Endogenous Peptide Substances Products, Services and Solutions
Table 82. Revenue (US$ Million) in Endogenous Peptide Substances Business of Peptide Institute (2018-2023)
Table 83. Peptide Institute Recent Developments
Table 84. Abbexa Basic Information List
Table 85. Abbexa Description and Business Overview
Table 86. Abbexa Endogenous Peptide Substances Products, Services and Solutions
Table 87. Revenue (US$ Million) in Endogenous Peptide Substances Business of Abbexa (2018-2023)
Table 88. Abbexa Recent Developments
Table 89. Phoenix Pharmaceuticals Basic Information List
Table 90. Phoenix Pharmaceuticals Description and Business Overview
Table 91. Phoenix Pharmaceuticals Endogenous Peptide Substances Products, Services and Solutions
Table 92. Revenue (US$ Million) in Endogenous Peptide Substances Business of Phoenix Pharmaceuticals (2018-2023)
Table 93. Phoenix Pharmaceuticals Recent Developments
Table 94. Creative Peptides Basic Information List
Table 95. Creative Peptides Description and Business Overview
Table 96. Creative Peptides Endogenous Peptide Substances Products, Services and Solutions
Table 97. Revenue (US$ Million) in Endogenous Peptide Substances Business of Creative Peptides (2018-2023)
Table 98. Creative Peptides Recent Developments
Table 99. North America Endogenous Peptide Substances Market Size by Country (2018-2023) & (US$ Million)
Table 100. North America Endogenous Peptide Substances Market Size by Country (2024-2033) & (US$ Million)
Table 101. Europe Endogenous Peptide Substances Market Size by Country (2018-2023) & (US$ Million)
Table 102. Europe Endogenous Peptide Substances Market Size by Country (2024-2033) & (US$ Million)
Table 103. Asia-Pacific Endogenous Peptide Substances Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 104. Asia-Pacific Endogenous Peptide Substances Market Size by Region (2018-2023) & (US$ Million)
Table 105. Asia-Pacific Endogenous Peptide Substances Market Size by Region (2024-2033) & (US$ Million)
Table 106. Asia-Pacific Endogenous Peptide Substances Market Share by Region (2018-2023)
Table 107. Asia-Pacific Endogenous Peptide Substances Market Share by Region (2024-2033)
Table 108. Latin America Endogenous Peptide Substances Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 109. Latin America Endogenous Peptide Substances Market Size by Country (2018-2023) & (US$ Million)
Table 110. Latin America Endogenous Peptide Substances Market Size by Country (2024-2033) & (US$ Million)
Table 111. Middle East & Africa Endogenous Peptide Substances Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 112. Middle East & Africa Endogenous Peptide Substances Market Size by Country (2018-2023) & (US$ Million)
Table 113. Middle East & Africa Endogenous Peptide Substances Market Size by Country (2024-2033) & (US$ Million)
Table 114. Endogenous Peptide Substances Market Trends
Table 115. Endogenous Peptide Substances Market Drivers
Table 116. Endogenous Peptide Substances Market Challenges
Table 117. Endogenous Peptide Substances Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Endogenous Peptide Substances Market Size Year-over-Year 2018-2033 & (US$ Million)
Figure 2. Global Endogenous Peptide Substances Market Size (US$ Million), 2018 VS 2022 VS 2033
Figure 3. Global Endogenous Peptide Substances Market Share by Regions: 2022 VS 2033
Figure 4. Global Endogenous Peptide Substances Forecasted Market Size Share by Region (2024-2033)
Figure 5. North America Endogenous Peptide Substances Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 6. Europe Endogenous Peptide Substances Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 7. Asia-Pacific Endogenous Peptide Substances Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 8. Latin America Endogenous Peptide Substances Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 9. Middle East & Africa Endogenous Peptide Substances Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 10. Product Picture of Neuropeptides
Figure 11. Global Neuropeptides Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 12. Product Picture of Hormones
Figure 13. Global Hormones Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 14. Product Picture of Cytokines
Figure 15. Global Cytokines Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 16. Product Picture of Peptide Hormones
Figure 17. Global Peptide Hormones Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 18. Product Picture of Bioactive Peptides
Figure 19. Global Bioactive Peptides Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 20. Global Endogenous Peptide Substances Market Size Share by Type: 2022 & 2033
Figure 21. North America Endogenous Peptide Substances Revenue Market Share by Type (2018-2033)
Figure 22. Europe Endogenous Peptide Substances Revenue Market Share by Type (2018-2033)
Figure 23. Asia-Pacific Endogenous Peptide Substances Revenue Market Share by Type (2018-2033)
Figure 24. Latin America Endogenous Peptide Substances Revenue Market Share by Type (2018-2033)
Figure 25. Middle East and Africa Endogenous Peptide Substances Revenue Market Share by Type (2018-2033)
Figure 26. Research Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 27. Medicine Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 28. Others Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 29. Global Endogenous Peptide Substances Market Size Share by Application: 2022 & 2033
Figure 30. North America Endogenous Peptide Substances Revenue Market Share by Application (2018-2033)
Figure 31. Europe Endogenous Peptide Substances Revenue Market Share by Application (2018-2033)
Figure 32. Asia-Pacific Endogenous Peptide Substances Revenue Market Share by Application (2018-2033)
Figure 33. Latin America Endogenous Peptide Substances Revenue Market Share by Application (2018-2033)
Figure 34. Middle East and Africa Endogenous Peptide Substances Revenue Market Share by Application (2018-2033)
Figure 35. Endogenous Peptide Substances Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 36. Global Top 5 and Top 10 Players Endogenous Peptide Substances Market Share in 2022
Figure 37. North America Endogenous Peptide Substances Market Share by Country (2018-2033)
Figure 38. United States Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 39. Canada Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 40. Germany Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 41. France Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 42. U.K. Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 43. Italy Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 44. Russia Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 45. Nordic Countries Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 46. Asia-Pacific Endogenous Peptide Substances Market Share by Region (2018-2033)
Figure 47. China Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 48. Japan Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 49. South Korea Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 50. Southeast Asia Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 51. India Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 52. Australia Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 53. Latin America Endogenous Peptide Substances Market Share by Country (2018-2033)
Figure 54. Mexico Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 55. Brazil Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 56. Middle East & Africa Endogenous Peptide Substances Market Share by Country (2018-2033)
Figure 57. Turkey Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 58. Saudi Arabia Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 59. UAE Endogenous Peptide Substances Market Size (2018-2033) & (US$ Million)
Figure 60. Bottom-up and Top-down Approaches for This Report